Please login to the form below

IBD Registry wins Communiqué award for COVID-19 tool

The IBD Registry has won a coveted Communiqué award in recognition of its collaborative efforts in creating the COVID-19 IBD Risk Tool for people with inflammatory bowel disease (IBD).

The IBD Registry has won a coveted Communiqué award in recognition of its collaborative efforts in creating the COVID-19 IBD Risk Tool for people with inflammatory bowel disease (IBD).

The entry was supported by agency partner Dovetail and judged alongside many high-profile candidates in the new Agility and Flexibility category, brought in this year to recognise healthcare communications responses to the COVID-19 pandemic.

The COVID-19 IBD Risk Tool was created in just eight days, thanks to the Registry’s data governance infrastructure and strong capability. The organisation worked closely with partners at the British Society of Gastroenterology and Crohn’s and Colitis UK, with vital support from sponsors including Amgen, Galapagos, Gilead and Tillotts UK.

The patient-friendly self-assessment risk tool aimed to reassure patients with IBD and support hospital IBD teams at the start of the COVID-19 shielding programme.

The judges said they were “impressed with the rapid and robust strategic response and how Dovetail and IBD Registry’s collaborative nature showed a huge degree of flexibility”.

Chief Executive Liz Dobson said: “We’re delighted to win this prestigious award. We set out to solve a data problem. What we achieved was a way of giving patients knowledge that empowers them to understand and manage their own disease, in only eight days from concept to launch. Our tool also shows clinicians the benefit of linking patient-entered and clinical data together, giving clinical teams a 360-degree view of each patient.”

The Communiqué awards ceremony was held the Grosvenor House hotel in London on 1st September.

About the IBD Registry

The purpose of the IBD Registry is to improve the health of people living with inflammatory bowel disease in the UK by the collection and analysis of data to increase understanding of the care of people with IBD and their treatments and to facilitate research. We do this by collecting and analysing data from IBD patients nationally. Working with over 175 hospitals in the UK and with over 80,000 patient-level records, we are one of the largest IBD registries in Europe

For further information contact:

Rachel Hunter
Communications and Engagement Manager
IBD Registry
rachel.hunter@ibdregistry.org.uk

21st September 2021

Share

Company Details

Dovetail

020 3176 6435

Contact Website

Address:
20 Marsden Road
London
SE15 4EE
United Kingdom

Latest content on this profile

IBD Registry wins Communiqué award for COVID-19 tool
The IBD Registry has won a coveted Communiqué award in recognition of its collaborative efforts in creating the COVID-19 IBD Risk Tool for people with inflammatory bowel disease (IBD).
Dovetail
DOVETAIL & IBD REGISTRY WIN AGILITY AND FLEXIBILITY AWARD AT COMMUNIQUÉ 2021
The award was the first to be won in Communiqué’s new AGILITY AND FLEXIBILITY category.
Dovetail
Dovetail partners with Tillotts AG to map management of C. difficile infection in Europe
Specialist stakeholder engagement consultancy Dovetail, based in London, UK, have announced a new partnership with Tillotts Pharma AG to support the launch of Tillotts’ recent acquisition DIFICLIR™ in the EU.
Dovetail
Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
Specialist healthcare consultancy Dovetail launches new collaboration skills training in response to client demand.
Dovetail
Joint working that works

Dovetail
Joint Working That Works
Claire Munro blogs about a recent Dovetail workshop on best practice in collaboration between industry and the NHS.
Dovetail